Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin

被引:23
作者
Lewin, SN
Mutch, DG
Whitcomb, BP
Liapis, H
Herzog, TJ
机构
[1] Washington Univ, Sch Med, Div Gynecol Oncol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA
[3] Columbia Univ, Div Gynecol Oncol, New York, NY 10027 USA
关键词
D O I
10.1016/j.ygyno.2004.12.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Hemolytic uremic syndrome (HUS) is a rare coagulation disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia and acute uremia. Reports have described this fatal syndrome in association with cytotoxic agents. To our knowledge, no case reports of HUS in ovarian cancer patients receiving treatment with combination gemcitabine and pegylated liposomal doxorubicin (PLD) have been reported. Case Reports. Three patients with recurrent ovarian carcinoma each developed profound hypertension and peripheral edema while receiving combination gemcitabine and PLD. The first patient had rapid hemolysis, thrombocytopenia, renal failure and respiratory distress. The other patients experienced slowly progressive renal failure and mild hematologic abnormalities. Two of the three patients had favorable outcomes. Conclusion. The reported incidence of gemcitabine-induced HUS is rare. Clinicians should suspect HUS if blood pressure elevation or peripheral edema develop. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:228 / 233
页数:6
相关论文
共 14 条
[1]   MICROANGIOPATHIC HAEMOLYTIC ANAEMIA - POSSIBLE ROLE OF VASCULAR LESIONS IN PATHOGENESIS [J].
BRAIN, MC ;
DACIE, JV ;
HOURIHANE, DOB .
BRITISH JOURNAL OF HAEMATOLOGY, 1962, 8 (04) :358-&
[2]  
Citarrella P, 2002, ANTICANCER RES, V22, P1183
[3]   Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer [J].
D'Agostino, G ;
Ferrandina, G ;
Garganese, G ;
Salerno, MG ;
Lorusso, D ;
Farnetano, MG ;
Mancuso, S ;
Scambia, G .
ONCOLOGY, 2002, 62 (02) :110-114
[4]   Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine [J].
Flombaum, CD ;
Mouradian, JA ;
Casper, ES ;
Erlandson, RA ;
Benedetti, F .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (03) :555-562
[5]   Phase 1 study of pegylated liposomal doxorubin and gemcitabine in patients with advanced malignancies [J].
Fracasso, PM ;
Blum, KA ;
Tan, BR ;
Fears, CL ;
Bartlett, NL ;
Arquette, MA ;
Clark, RS .
CANCER, 2002, 95 (10) :2223-2229
[6]  
Fung MC, 1999, CANCER-AM CANCER SOC, V85, P2023
[7]  
Green MR, 1996, SEMIN ONCOL, V23, P32
[8]   Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine [J].
Gross, M ;
Hiesse, C ;
Kriaa, F ;
Goldwasser, F .
ANTI-CANCER DRUGS, 1999, 10 (06) :533-536
[9]   Clinical, toxicological and pharmacological aspects of gemcitabine [J].
Guchelaar, HJ ;
Richel, DJ ;
vanKnapen, A .
CANCER TREATMENT REVIEWS, 1996, 22 (01) :15-31
[10]   Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy [J].
Lhotta, K ;
Kühr, T ;
Rumpelt, HJ ;
Wöll, E ;
Thaler, J ;
König, P .
AMERICAN JOURNAL OF NEPHROLOGY, 1999, 19 (05) :590-593